Released Aug 10, 2023, after the close
10-Q filed Aug 10, 2023, 41 days after period end · 0000950170-23-041416
Q2 2023 · 10-Q
Revenue$10.41M$10.41M −62.9% vs Q2 2022−17.8% vs Q1 2023
Net Income-$38.52M-$38.52M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.64-$0.64 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$46,179,000N/M
Operating Cash Flowderived-$31,195,000N/M
Margins · derived
Operating margin-443.5%−374.5 pt vs Q2 2022
Net margin-370.0%−277.4 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $10.41M | $28.10M | $28.05M | $9.47M |
| Net Income | -$38.52M | -$26.01M | -$6.15M | $29.87M |
| EPS Diluted | -$0.64 | -$0.55 | -$0.13 | $0.94 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR